-
Notifications
You must be signed in to change notification settings - Fork 26
Commit
This commit does not belong to any branch on this repository, and may belong to a fork outside of the repository.
- Loading branch information
Showing
6 changed files
with
23 additions
and
6 deletions.
There are no files selected for viewing
This file contains bidirectional Unicode text that may be interpreted or compiled differently than what appears below. To review, open the file in an editor that reveals hidden Unicode characters.
Learn more about bidirectional Unicode characters
This file contains bidirectional Unicode text that may be interpreted or compiled differently than what appears below. To review, open the file in an editor that reveals hidden Unicode characters.
Learn more about bidirectional Unicode characters
This file contains bidirectional Unicode text that may be interpreted or compiled differently than what appears below. To review, open the file in an editor that reveals hidden Unicode characters.
Learn more about bidirectional Unicode characters
This file contains bidirectional Unicode text that may be interpreted or compiled differently than what appears below. To review, open the file in an editor that reveals hidden Unicode characters.
Learn more about bidirectional Unicode characters
This file contains bidirectional Unicode text that may be interpreted or compiled differently than what appears below. To review, open the file in an editor that reveals hidden Unicode characters.
Learn more about bidirectional Unicode characters
This file contains bidirectional Unicode text that may be interpreted or compiled differently than what appears below. To review, open the file in an editor that reveals hidden Unicode characters.
Learn more about bidirectional Unicode characters
| Original file line number | Diff line number | Diff line change |
|---|---|---|
| @@ -1,10 +1,10 @@ | ||
| [ | ||
| { | ||
| "content": "Can you summarize this content into 2-3 sentences I can share in an email for the following target:\n\nMId-Aged HCPs Treating Frail Patients Preferring Safety over Efficacy\n\nFocus is 1 for low 5 for high on the Scale\nTreatment Goals\n\nScale: Relief of Symptoms to Full Remission = 4.5\nEfficacy vs Safety Focus\n\nScale: High Safety to High Efficacy = 1\nPlacement in Adoption Ladder\n\nScale: Laggards 1 to Early Adopters = 4\nKOL Influence\n\nScale: Low 1 to High 5 = 2.5\nChannel Preferences\n\nScale: Traditional - F2F 1 to Digital = 3\nSource of Information\n\nScale: Rep\/MSL 1 to Research Publications = 4.5\nPerceptions on Competitors\n\nScale: Competitor 1 to Pharma Co = 4.5\nSuitability to Patient Types\n\nScale: Frail 1 to Healthy = 1", | ||
| "content": "Can you summarize this for me", | ||
| "role": "user" | ||
| }, | ||
| { | ||
| "content": "**Role**\nA Summarization and Prompt Answering system that sticks to the context in this prompt.\n**Task**\nUsing the context of the prompt and the users query return a concise, clear, and accurate response.\n**Format**\nDeliver the response in a concise, clear Markdown format (Text). Use quotes as needed from the context.\n\n[DO NOT INCLUDE THE ABOVE IN THE RESPONSE]\n\n**The User's Query**:\n```Can you summarize this content into 2-3 sentences I can share in an email for the following target:\n\nMId-Aged HCPs Treating Frail Patients Preferring Safety over Efficacy\n\nFocus is 1 for low 5 for high on the Scale\nTreatment Goals\n\nScale: Relief of Symptoms to Full Remission = 4.5\nEfficacy vs Safety Focus\n\nScale: High Safety to High Efficacy = 1\nPlacement in Adoption Ladder\n\nScale: Laggards 1 to Early Adopters = 4\nKOL Influence\n\nScale: Low 1 to High 5 = 2.5\nChannel Preferences\n\nScale: Traditional - F2F 1 to Digital = 3\nSource of Information\n\nScale: Rep\/MSL 1 to Research Publications = 4.5\nPerceptions on Competitors\n\nScale: Competitor 1 to Pharma Co = 4.5\nSuitability to Patient Types\n\nScale: Frail 1 to Healthy = 1```\n\n**Context from the database search of documents for Response**:\n```Safety\nGuidelines\nSummary:\n\n MHRA Drug Safety Update October 2012, vol 6, issue 3: S1 (http:\/\/www.mhra.gov.uk\/Safetyinformation\/DrugSafetyUpdate\/CON199570)\n NICE Medicines Evidence Commentary 30\" Nov 2012 (www.evidence.nhs.uk) Over the last 8 years there have been several warnings from the MHRA regarding the cardiovascular risks with some non-steroidal anti-inflammatory agents (NSAIDs), specifically diclofenac. Despite this, there continues to be significant prescribing of diclofenac; it accounts for 21% of all NSAID items in the East Midlands. In some areas nearly a third of prescriptions for NSAIDs in primary care are for diclofenac. Ibuprofen and naproxen make up 64% of all NSAID prescriptions in the East Midlands. However, in some areas only half of all NSAID prescriptions are for these preferred agents. idlands. However, in some areas only half of all NSAID prescriptions are for these preferred agents. Summary:\nMedication \tDosage \tCost (28 days supply)\nIbuprofen 400mg \ttds \t3.36\nNaproxen 500mg \tbd \t4.34\nDiclofenac 50mg \ttds \t2.70\nDiclofenac MR 75mg \tbd \t12.92\nDiclofenac MR 100mg \tdaily \t8.00\nParacetamol 1g \tqds \t6.45\n\nCosts for 28 days supply. Taken from Drug Tariff June 2013. Doses are a guide and do not imply therapeutic equivalence. Recent cohort data have confirmed previous safety warnings that diclofenac has a higher risk of thrombotic events (including Mi and stroke) than naproxen or low-dose ibuprofen. Even a few days of treatment may increase risk, both in healthy individuals and those with cardiovascular disease. High doses of ibuprofen may also have an increased risk. Two meta-analyses have both estimated that, compared with placebo, diclofenac causes around three additional major vascular events per 1000 patients per year, with one such event causing death. Diclofenac continues to be widely prescribed; in s per year, with one such event causing death. Diclofenac continues to be widely prescribed; in some areas of the East Midlands nearly a third of NSAID prescribing is for diclofenac. Ibuprofen (1200mg per day or less) or naproxen (1000mg per day or less) are recommended first-line agents, combined with gastro-protection if at high risk for gastrointestinal adverse events. NSAIDs should be prescribed for the shortest time and lowest dose necessary to control symptoms. In 2005 the European Committee for Medicinal Products for Human Use (CHMP) identified an increased risk of thrombotic events, such as myocardial infarction (MI) or stroke with COX-2 inhibitors. In 2006, they advised that a similar link may exist with non-specific NSAIDs, in particular diclofenac, particularly if used at high doses for long-term treatment. In October 2012, the MHRA confirmed the previous findings, based on a more recent review of the evidence. The currently available data consistently indicate that the risk of Mi, stroke or other thrombotic events is higher for diclofenac t sistently indicate that the risk of Mi, stroke or other thrombotic events is higher for diclofenac than other widely used non-selective NSAIDs and similar to selective COX-2 inhibitors. Two meta-analyses have both estimated that, compared with placebo, a COX-2 inhibitor or diclofenac causes around three additional major vascular events per 1000 paganie s oyee pattents back event vasula tak. High- 55 Du prorea 2400mg daily) also significantly increased the risk of major coronary events, but its safety requires further study as there were many fewer relevant vascular events. Naproxen did not see Over the last 8 years there have been several warnings from the MHRA regarding the cardiovascular risks with some non-steroidal anti-inflammatory agents (NSAIDs), specifically diclofenac. Despite this, there continues to be significant prescribing of diclofenac; it accounts for 21% of all NSAID items in the East Midlands. In some areas nearly a third of prescriptions for NSAIDs in primary care are for diclofenac. Ibuprofen and naproxen make up 64% of all NSAID prescriptions in the East Midlands. However, in some areas only half of all NSAID prescriptions are for these preferred agents. idlands. However, in some areas only half of all NSAID prescriptions are for these preferred agents. Recent cohort data have confirmed previous safety warnings that diclofenac has a higher risk of thrombotic events (including Mi and stroke) than naproxen or low-dose ibuprofen. Even a few days of treatment may increase risk, both in healthy individuals and those with cardiovascular disease. High doses of ibuprofen may also have an increased risk. Two meta-analyses have both estimated that, compared with placebo, diclofenac causes around three additional major vascular events per 1000 patients per year, with one such event causing death. Diclofenac continues to be widely prescribed; in s per year, with one such event causing death. Diclofenac continues to be widely prescribed; in some areas of the East Midlands nearly a third of NSAID prescribing is for diclofenac. Ibuprofen (1200mg per day or less) or naproxen (1000mg per day or less) are recommended first-line agents, combined with gastro-protection if at high risk for gastrointestinal adverse events. NSAIDs should be prescribed for the shortest time and lowest dose necessary to control symptoms. In 2005 the European Committee for Medicinal Products for Human Use (CHMP) identified an increased risk of thrombotic events, such as myocardial infarction (MI) or stroke with COX-2 inhibitors. In 2006, they advised that a similar link may exist with non-specific NSAIDs, in particular diclofenac, particularly if used at high doses for long-term treatment. In October 2012, the MHRA confirmed the previous findings, based on a more recent review of the evidence. The currently available data consistently indicate that the risk of Mi, stroke or other thrombotic events is higher for diclofenac t sistently indicate that the risk of Mi, stroke or other thrombotic events is higher for diclofenac than other widely used non-selective NSAIDs and similar to selective COX-2 inhibitors. Two meta-analyses have both estimated that, compared with placebo, a COX-2 inhibitor or diclofenac causes around three additional major vascular events per 1000 paganie s oyee pattents back event vasula tak. High- 55 Du prorea 2400mg daily) also significantly increased the risk of major coronary events, but its safety requires further study as there were many fewer relevant vascular events. Naproxen did not see afety requires further study as there were many fewer relevant vascular events. Naproxen did not seem to increase the risk of major vascular events. Ibuprofen (1200mg per day or less) and naproxen (1000mg per day or less) are considered to have the most favourable cardiovascular safety profiles of all non-selective NSAIDs. All NSAIDs increased the risk of heart failure and of gastrointestinal (GI) events; naproxen having a higher risk of Gl events than ibuprofen or diclofenac. Results from a Danish cohort study of patients who had suffered a MI suggested that even short-term use of NSAIDs ```", | ||
| "content": "**Role**\nA Summarization and Prompt Answering system that sticks to the context in this prompt.\n**Task**\nUsing the context of the prompt and the users query return a concise, clear, and accurate response.\n**Format**\nDeliver the response in a concise, clear Markdown format (Text). Use quotes as needed from the context.\n\n[DO NOT INCLUDE THE ABOVE IN THE RESPONSE]\n\n**The User's Query**:\n```Can you summarize this for me```\n\n**Context from the database search of documents for Response**:\n```Read how LaraLlama Embeds Documents Content Read how LaraLlama Embeds Documents Read more about it here https:\/\/medium.com\/@alnutile\/local-llm-and-laravel-in-10-minutes-with-local-llm-embedding-for-free-ac96e49288d2Posted on: June 8th, 2024 On: Blog how Share this on social media Facebook Twitter Copyright 2024. LaraLlama LaraLlama.io Consulting Blog Contact Us Reach Us [email protected] +1-413-225-1844 Newsletter Doc Site Released! Content Doc Site Released! Start learning about LaraLlama at https:\/\/docs.larallama.io\/See numerous Use Cases to quickly, with no code, start automation common workflows at your company! https:\/\/docs.larallama.io\/use-cases.html Posted on: June 7th, 2024 On: Press Release inspiration technology newsletter Share this on social media Facebook Twitter Copyright 2024. LaraLlama LaraLlama.io Consulting Blog Contact Us Reach Us [email protected] +1-413-225-1844 Newslette Turn your Docs into a Support Chat Widget Content Turn your Docs into a Support Chat Widget This YouTube video will show you how easily you can turn GitHub Webhooks into a unified Change-Log! Posted on: June 8th, 2024 By: LaraLlama Team On: Blog automations Share this on social media Facebook Twitter About the author LaraLlama Team A Team with 20+ years experience with Laravel and 2 years building LLM based applications Copyright 2024. LaraLlama LaraLlama.io Consulting Blog Contact Us Reach Us info Numerous UI Updates, Prompt Template Improvements, and More! Content Numerous UI Updates, Prompt Template Improvements, and More! More Than Just a New UIThis update lays the foundation for us as developers to work more efficiently on the system. By integrating DaisyUI https:\/\/daisyui.com\/, we now have access to a plethora of easy-to-use components. This shift moves us towards a more modular, Lego brick building approach for the UI while still utilizing Tailwind CSS. Prompting EverywhereThe goal of LaraLlama is to make prompting and automa LaraLamma - Email to Daily Report in 2 Steps - No Code Content LaraLamma - Email to Daily Report in 2 Steps - No Code Turn Marketing Emails, Customer Feedback Emails and more into a daily report sent to you or your team! Posted on: June 8th, 2024 By: LaraLlama Team On: Blog automations Share this on social media Facebook Twitter About the author LaraLlama Team A Team with 20+ years experience with Laravel and 2 years building LLM based applications Copyright 2024. LaraLlama LaraLlama.io Consulting Blog C Getting Started with LaraChain (LaraLamma) Content Getting Started with LaraChain (LaraLamma) This video will help you get started with LaraLlama.io Posted on: June 8th, 2024 By: LaraLlama Team On: Blog help intro Share this on social media Facebook Twitter About the author LaraLlama Team A Team with 20+ years experience with Laravel and 2 years building LLM based applications Copyright 2024. LaraLlama LaraLlama.io Consulting Blog Contact Us Reach Us [email protected] +1-413-225-1844 Ne LaraLlama Standards Checking Tool Content LaraLlama Standards Checking Tool We introduce in this release a Standards Checking tool. Just imagine you have a documentation team and when they write new content in their CMS it can then check the API LaraLlama provides to check it matches the Standards in your Collection. One - Easily choose a persona!Two - Find any of the ones you made in the \"Style Guide\" areaThree - LaraLlama will auto discover the tool to use but this helps for some LLMs like Ollama that do not have tools 100% working yet. Just upload the docume Introducing LaraLlamas New Target Audience Feature: Tailor Your Prompts with Precision Content Introducing LaraLlamas New Target Audience Feature: Tailor Your Prompts with Precision LaraLlama.io is excited to announce the launch of its latest feature, designed to revolutionize how users create prompts by allowing them to choose and define target audiences with ease. This enhancement empowers users to craft highly effective and relevant prompts tailored to specific audiences, ensuring their content hits the mark every time. With LaraLlamas innovative user i```", | ||
| "role": "assistant" | ||
| } | ||
| ] |